Partial response to erlotinib in a patient with imatinib-refractory sacral chordoma.

Saurav VermaSurya Prakash VadlamaniShamim Ahmed ShamimAdarsh BarwadSameer RastogiS T Arun Raj

Published in: Clinical sarcoma research (2020)

As seen in previously reported cases, erlotinib is a therapeutic option in advanced chordoma, even in imatinib refractory cases and thus warrants exploration of its therapeutic role in prospective clinical trials.

Keyphrases

clinical trial
chronic myeloid leukemia
advanced non small cell lung cancer
epidermal growth factor receptor
case report
randomized controlled trial
phase ii
tyrosine kinase